My interests have covered basic, clinical and public health cardiovascular research, prevention, treatment and policy. Particular contributions include efficacy and mechanisms of the benefits of physical activity, sympathetic pathophysiology of CVD, vascular biology, clinical pharmacology of anti-hypertensives and some of the earliest clinical trials globally of major drug classes. Translation and implementation have been a preoccupation throughout with the emergence of implementation science providing a recent focus at Sydney Health Partners. As Director of the Baker Institute I founded Nucleus Network, now a large commercial entity conducting early phase clinical trials in centres in Australia and the U.S.